INS and type 2 diabetes mellitus: Between April 1, 2015, and April 30, 2021, 95 564 and 838 996 people with type 2 diabetes were identified with at least 1 prescription claim(s) for Gla-300 or long-acting basal insulins/NPH, respectively.